Improving domain definition and outcome instrument selection: Lessons learned for OMERACT from imaging
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Objectives: Imaging is one of the most rapidly evolving fields in medicine. Unfortunately, many imaging technologies have been applied as measurement instruments without rigorous evaluation of the evidence supporting their truth, discriminatory capability and feasibility for that context of use. The Outcome Measures in Rheumatology (OMERACT) Filter 2.1 Instrument Selection Algorithm (OFISA) is used to evaluate such evidence for use of an instrument in a research setting. The objectives of this work are to: [1] define and describe the key conceptual aspects that are essential for the evaluation of imaging as an outcome measurement instrument and [2] describe how these aspects can be assessed through OFISA. Methods: Experts in imaging and/or methodology met to formalize concepts and define key steps. These concepts were discussed with a team of patient research partners with interest in imaging to refine technical and methodological aspects into comprehensible information. A workshop was held at OMERACT2020 and feedback was incorporated into existing OMERACT process for domain and instrument selection. Results: Three key lessons were identified: (1) a clear definition of the domain we want to measure is a necessary prerequisite to the selection of a good instrument, (2) the sources of variability that can directly influence the instrument should be clearly identified, (3) incorporating these first two lessons into OFISA improves the quality of every instrument selection process. Conclusions: The incorporation of these lessons in the updated OMERACT Filter (now 2.2) will improve the quality of the selection process for all types of outcome measurement instruments.
| Originalsprog | Engelsk |
|---|---|
| Tidsskrift | Seminars in Arthritis and Rheumatism |
| Vol/bind | 51 |
| Udgave nummer | 5 |
| Sider (fra-til) | 1125-1133 |
| ISSN | 0049-0172 |
| DOI | |
| Status | Udgivet - 2021 |
Bibliografisk note
Funding Information:
PGC is supported in part through the NIHR Leeds Biomedical Research Centre. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health. This article was prepared by Victor Sloan in his personal capacity. The views expressed are his own and do not reflect the views of the Peace Corps or the US Government. Thank you to the workshop participants including the facilitators, content experts and reporters:, Catherine Hofstetter, Dorcas Beaton, Tarimobo Otobo, Sofia Ramiro, Bev Shea, Karine Toupin April, D?sir?e van der Heijde, Victor Sloan, Lyn March, Lene Terslev, Simon D?cary, Francesca Ingegnoli, Jeffrey Chau, Lee Simon, Walter Maksymowych, Mikkel ?stergaard, Alexa Meara, Robin Christensen, Maarten de Wit, Maria Stoenoiu, Anne Boel, Maarten Boers, Robert Landewe, Dan Zhao, Enrico De Lorenzis, Vibeke Strand, Mariana Ivanova, Win Min Oo, Deb Constien, Annette Mckinnon, Kei Ikeda, Philip Conaghan, Michael Backhouse, Sarah Mackie, Alison Hoens, Grayson Schultz, Zahi Touma, Peter Tugwell, Marion van Rossum, Bing Bingham, Tom Buttel, Annelies Boonen, Andrea Doria, Sabrina Mai Nielsen, Corrado Campochiaro, Raouf Hajji, Charles Goldsmith, Ihsane Hmamouchi, Thasia Woodworth, Niti Goel, Mikael Boesen, Sam Michel Cembalo, Ingrid de Groot, Codruta Zabalan, Manouk de Hooge, This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
Funding Information:
PGC is supported in part through the NIHR Leeds Biomedical Research Centre. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health.
Funding Information:
Mikkel Østergaard reports grants, personal fees and non-financial support from AbbVie, grants, personal fees and non-financial support from BMS, personal fees from Boehringer-Ingelheim, personal fees from Eli Lilly, personal fees and non-financial support from Janssen, grants, personal fees and non-financial support from Merck, personal fees and non-financial support from Pfizer, personal fees and non-financial support from Roche, grants, personal fees and non-financial support from UCB, grants and personal fees from Celgene, personal fees from Sanofi, personal fees from Regeneron, grants, personal fees and non-financial support from Novartis, personal fees from Gilead, outside the submitted work.
Publisher Copyright:
© 2021
ID: 279627767